STK39 Antibody

What is STK39 and what cellular pathways is it involved in?

STK39 is a serine/threonine kinase that plays a critical role in cellular stress response pathways. It becomes activated in response to hypotonic stress, leading to phosphorylation of several cation-chloride-coupled cotransporters . STK39 is also involved in the WNK signaling pathway where it mediates inhibition of SLC4A4, SLC26A6, and CFTR activities . Recent research has revealed that STK39 positively regulates the ERK signaling pathway and interacts with PLK1 to promote hepatocellular carcinoma (HCC) progression . Additionally, STK39 has been identified as a hypertension susceptibility gene through whole-genome association studies .

What types of STK39 antibodies are available for research applications?

Multiple types of STK39 antibodies are available for research, varying in several key aspects:

These antibodies are validated for multiple applications including Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), and immunoprecipitation (IP) .

How do I select the appropriate STK39 antibody for my specific research needs?

When selecting an STK39 antibody, consider these key factors:

• Experimental application: Different antibodies are validated for specific applications. For example, if performing immunofluorescence labeling, choose antibodies specifically validated for IF (typically at 1:100 dilution) .

• Species reactivity: Ensure the antibody recognizes STK39 in your experimental model organism. Available antibodies react with human, mouse, and/or rat STK39 .

• Target region: Depending on your research focus, select antibodies targeting:

  • The N-terminal region for general STK39 detection

  • The C-terminal region for specific epitope recognition

  • Phosphorylation sites (Ser311, Ser325) for studying activation states

• Clonality: Choose polyclonal antibodies for higher sensitivity or monoclonal/recombinant antibodies for higher specificity and batch-to-batch consistency .

• Validation data: Review the available validation data for your specific application and sample type. Most manufacturers provide images of Western blots, IHC sections, or IF staining .

For phosphorylation studies, phospho-specific antibodies targeting Ser311 or Ser325 are available with recommended working dilutions of 1:500-1:2000 for Western blotting .

What are the optimal conditions for detecting STK39 using Western blotting?

For optimal Western blot detection of STK39, follow these methodological guidelines:

• Sample preparation:

  • For tissue samples: Homogenize in RIPA buffer containing protease and phosphatase inhibitors

  • For cell lines: Lyse cells in buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and protease/phosphatase inhibitor cocktail

• Protein loading and separation:

  • Load 20-50 μg of protein per lane

  • Use 8-10% SDS-PAGE gels for optimal separation (STK39 has a calculated molecular weight of 59 kDa)

• Transfer conditions:

  • Transfer to PVDF membrane at 100V for 90 minutes in cold transfer buffer

  • Verify transfer efficiency with Ponceau S staining

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or 5% BSA (especially for phospho-specific antibodies) in TBST for 1 hour at room temperature

  • Dilute primary STK39 antibody at 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

  • Wash 3x with TBST, 5 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

  • Wash 3x with TBST, 5 minutes each

• Detection:

  • Use enhanced chemiluminescence (ECL) detection reagents

  • Typical exposure times range from 30 seconds to 5 minutes depending on expression levels

For phospho-specific STK39 detection, always include phosphatase inhibitors in all buffers and consider using phospho-blocking peptides as controls to verify specificity .

How can I optimize immunohistochemistry protocols for STK39 detection in tissue sections?

For optimal immunohistochemical detection of STK39 in tissue sections:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin following standard protocols

  • Section tissues at 4-6 μm thickness

• Antigen retrieval (critical step):

  • Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Heat in pressure cooker or microwave for 15-20 minutes

  • Allow slides to cool to room temperature in retrieval solution (approximately 20 minutes)

• Blocking and antibody incubation:

  • Block endogenous peroxidase activity with 3% H₂O₂ for 10 minutes

  • Block non-specific binding with 5% normal serum from the species of the secondary antibody

  • Dilute primary STK39 antibody at 1:100-1:300 in antibody diluent

  • Incubate overnight at 4°C or 60 minutes at room temperature in a humidified chamber

• Detection system:

  • Use biotin-streptavidin or polymer-based detection systems

  • Develop with DAB substrate for 2-5 minutes (monitor under microscope)

  • Counterstain with hematoxylin for 30 seconds

  • Dehydrate, clear, and mount with permanent mounting medium

• Controls:

  • Include positive control tissues known to express STK39 (kidney, liver)

  • Include negative controls by omitting primary antibody

  • Consider using STK39-knockout tissue (if available) as specificity control

For multiplex immunofluorescence detection, dilute STK39 antibody at 1:100 and use fluorophore-conjugated secondary antibodies specific to the host species of the primary antibody .

How can I validate the specificity of an STK39 antibody in my experimental system?

Rigorous validation of STK39 antibody specificity is crucial for reliable results. Implement these methodological approaches:

• Knockout/knockdown validation:

  • Generate STK39-knockout cell lines using CRISPR/Cas9 system (e.g., target sequence: 5'-CGGCGGCACAGGCTGTCGGC-3')

  • Alternatively, use siRNA or shRNA to knockdown STK39 expression

  • Compare antibody reactivity between wild-type and knockout/knockdown samples using Western blot or immunocytochemistry

• Overexpression validation:

  • Transfect cells with STK39 expression vector

  • Compare antibody reactivity in transfected versus non-transfected cells

  • Look for increased signal in overexpressing cells

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide

  • Perform parallel experiments with blocked and unblocked antibody

  • Specific signal should be abolished or significantly reduced in the blocked condition

• Cross-validation with multiple antibodies:

  • Use antibodies targeting different epitopes of STK39 (N-terminal, C-terminal, internal region)

  • Compare staining patterns across antibodies

  • Consistent patterns across antibodies suggest specific detection

• Mass spectrometry validation:

  • Perform immunoprecipitation with the STK39 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm presence of STK39 and known interacting partners (e.g., PLK1)

Research has shown successful validation of STK39 antibodies in multiple experimental systems, including mouse tissue for immunofluorescence labeling and human HCC cell lines for Western blotting .

What methodologies are most effective for studying STK39 phosphorylation and its signaling cascades?

To effectively study STK39 phosphorylation and downstream signaling cascades:

• Phospho-state specific detection:

  • Use phospho-specific antibodies targeting key sites:

    • pSer311 antibodies (dilution 1:500-1:2000 for WB)

    • pSer325 antibodies (dilution 1:500-1:2000 for WB)

  • Compare with total STK39 levels using general antibodies

  • Calculate phosphorylation ratios (phospho-STK39/total STK39)

• Kinase activity assays:

  • Immunoprecipitate STK39 from cell lysates

  • Perform in vitro kinase assays with recombinant substrates

  • Measure phosphorylation by autoradiography or phospho-specific antibodies

  • Include ATP-competitive inhibitors as negative controls

• Cellular stress response models:

  • Induce hypotonic stress by decreasing media osmolarity (e.g., 50% hypotonic solution)

  • Monitor temporal changes in STK39 phosphorylation (typically peaks at 15-30 minutes)

  • Track activation of downstream effectors (p38 MAPK pathway components)

  • Correlate STK39 phosphorylation with physiological responses (ion transport)

• Signaling pathway dissection:

  • Use RNA-seq to identify genes regulated by STK39 (as demonstrated in HCC studies)

  • Validate findings with RT-qPCR and Western blotting

  • Perform pathway enrichment analysis

  • Use specific pathway inhibitors (e.g., ERK pathway inhibitors) to establish dependency relationships

• Phosphorylation site mutants:

  • Generate phospho-mimetic (S→D/E) and phospho-resistant (S→A) mutants of key residues

  • Express in cell models and analyze functional consequences

  • Compare signaling outputs between wild-type and mutant proteins

Research has shown that STK39 positively regulates the ERK signaling pathway and interacts with PLK1 in promoting HCC progression, highlighting the importance of studying these specific signaling connections .

How can I design experiments to investigate STK39's role in cancer progression, particularly hepatocellular carcinoma?

To investigate STK39's role in cancer progression, particularly HCC, implement these experimental approaches:

• Expression analysis in clinical samples:

  • Compare STK39 expression between matched tumor and adjacent normal tissues using:

    • RT-qPCR for mRNA levels

    • Western blotting for protein levels

    • Immunohistochemistry for spatial distribution

  • Correlate expression with clinical parameters (tumor stage, patient survival)

  • Research has shown STK39 is markedly upregulated in HCC tumor tissues (approximately 62.5% of patients)

• Functional studies in cell models:

  • Knockdown approaches:

    • siRNA or shRNA for transient knockdown

    • CRISPR/Cas9 for complete knockout (target sequence: 5'-CGGCGGCACAGGCTGTCGGC-3')

  • Overexpression approaches:

    • Transfect cells with STK39 expression vectors

  • Analyze effects on:

    • Cell proliferation using CCK8 or trypan blue exclusion assays

    • Colony formation capacity

    • 3D culture growth

    • Cell cycle progression using PI staining and flow cytometry

    • Apoptosis using TUNEL or Annexin V/PI assays

• In vivo tumor models:

  • Inject STK39-knockdown/knockout cells subcutaneously in nude mice

  • Monitor tumor growth (volume and weight)

  • Analyze tumor sections for proliferation (Ki67), apoptosis (TUNEL), and signaling markers

  • Research shows that STK39 knockdown significantly reduced tumor volume and weight in xenograft models

• Mechanistic studies:

  • RNA-seq analysis of STK39-modulated cells

  • Mass spectrometry to identify interacting partners (e.g., PLK1)

  • Pathway activation analysis (e.g., ERK pathway)

  • Validation of key interactions by co-immunoprecipitation

  • Functional rescue experiments (e.g., re-expressing STK39 in knockout cells)

• Transcriptional regulation:

  • Analyze promoter activity using luciferase reporter assays

  • Identify transcription factors regulating STK39 (e.g., SP1)

  • Use ChIP assays to confirm binding to the STK39 promoter

Research has demonstrated that STK39 promotes HCC cell proliferation, migration, and invasion, while its knockdown arrests cells in G2/M phase and promotes apoptosis, suggesting it could be a potential therapeutic target .

What are the best experimental approaches to study STK39's role in hypertension and blood pressure regulation?

To investigate STK39's role in hypertension and blood pressure regulation:

• Genetic association studies:

  • Analyze STK39 SNPs in hypertensive and normotensive populations

    • Key SNPs of interest: rs6749447, rs3754777

    • Meta-analysis has shown significant association with SBP (p = 1.6 × 10⁻⁷ for rs6749447)

  • Estimated effect sizes: ~2 mmHg for SBP and ~1 mmHg for DBP per allele

  • Use different genetic models (additive, recessive, dominant) for analysis

  • Perform haplotype analysis of multiple SNPs within the STK39 gene

• Animal models:

  • Generate STK39 knockout or knockin mice

  • Monitor blood pressure using:

    • Radiotelemetry (gold standard)

    • Tail-cuff method (for screening)

    • Direct catheterization (acute measurements)

  • Challenge with salt-loading to assess salt-sensitivity

  • Analyze renal function (electrolyte handling, GFR)

• Cellular models of ion transport:

  • Culture renal epithelial cells expressing cation-chloride cotransporters

  • Manipulate STK39 expression (siRNA knockdown, CRISPR knockout, overexpression)

  • Measure ion transport using:

    • Radioactive ion flux assays

    • Fluorescent ion indicators

    • Electrophysiological methods (patch clamp)

  • Assess cotransporter phosphorylation status

• WNK-SPAK pathway investigation:

  • Study STK39 (SPAK) as part of the WNK signaling cascade

  • Analyze phosphorylation of NKCC2, NCC, and other downstream targets

  • Use phospho-specific antibodies against Ser311 and Ser325 of STK39

  • Explore interactions between WNK kinases and STK39 using co-immunoprecipitation

• Pharmacological approaches:

  • Test STK39 kinase inhibitors in cellular and animal models

  • Assess effects on blood pressure and renal ion handling

  • Combine with diuretics to evaluate synergistic effects

  • Study effects on compensatory mechanisms

Research has established STK39 as a hypertension susceptibility gene with potential clinical significance in blood pressure regulation .

How can phospho-specific STK39 antibodies be leveraged to investigate activation states in different physiological contexts?

Phospho-specific STK39 antibodies are powerful tools for investigating activation states across different physiological contexts:

• Mapping activation dynamics:

  • Use phospho-specific antibodies against key sites:

    • pSer311 antibodies (1:500-1:2000 for WB, 1:100-1:300 for IHC)

    • pSer325 antibodies

  • Perform time-course experiments after stimuli:

    • Hypotonic stress

    • Oxidative stress

    • Growth factor stimulation

  • Quantify relative phosphorylation levels normalized to total STK39

• Tissue-specific activation patterns:

  • Compare STK39 phosphorylation across tissues using multiplex immunohistochemistry

  • Correlate with expression of upstream regulators (WNK kinases) and downstream targets

  • Analyze changes under pathological conditions:

    • Hypertension models

    • Cancer tissues

    • Inflammatory conditions

• Single-cell resolution studies:

  • Use phospho-specific antibodies for flow cytometry (1:100 dilution)

  • Perform phospho-flow cytometry to quantify STK39 activation in heterogeneous cell populations

  • Combine with markers for specific cell types

  • Identify differential activation in subpopulations

• Pharmacological modulation:

  • Assess effects of kinase inhibitors on STK39 phosphorylation

  • Study impact of phosphatase inhibitors on maintaining phosphorylation state

  • Correlate phosphorylation changes with functional readouts

• Validation strategies:

  • Use phospho-blocking peptides as controls

  • Include phosphatase treatment controls

  • Compare with phosphorylation-site mutants (S→A)

  • Validate key findings with multiple antibody clones or detection methods

For Western blotting with phospho-specific antibodies, these methodological considerations are critical:

• Use phosphatase inhibitors in all buffers (50 mM NaF, 5 mM Na₃VO₄, 10 mM Na₄P₂O₇)

• Block membranes with 5% BSA rather than milk (milk contains phospho-proteins)

• Include phosphorylated peptide competition controls

• Strip and reprobe membranes for total STK39 to calculate phospho/total ratios

These approaches allow researchers to precisely track STK39 activation across different physiological and pathological contexts .

What are common issues encountered when using STK39 antibodies and how can they be resolved?

Common issues with STK39 antibodies and their solutions:

• High background in Western blots:

  • Problem: Non-specific binding or insufficient blocking

  • Solution:

    • Increase blocking time (2-3 hours at room temperature)

    • Try different blocking agents (5% milk, 5% BSA, commercial blockers)

    • Increase washing frequency and duration (5-6 washes, 10 minutes each)

    • Dilute primary antibody further (1:2000-1:5000)

    • Use highly purified antibody preparations

• Weak or no signal in immunostaining:

  • Problem: Insufficient antigen retrieval or low antibody sensitivity

  • Solution:

    • Optimize antigen retrieval (try different buffers: citrate pH 6.0 vs. EDTA pH 9.0)

    • Increase antibody concentration (1:50-1:100)

    • Extend primary antibody incubation (overnight at 4°C)

    • Use signal amplification systems (tyramide signal amplification)

    • Ensure sample has not degraded during processing

• Multiple bands in Western blot:

  • Problem: Degradation, post-translational modifications, or non-specific binding

  • Solution:

    • Add fresh protease inhibitors to lysis buffer

    • Use phosphatase inhibitors for phospho-specific detection

    • Run pre-adsorption controls with immunizing peptide

    • Compare with STK39 knockout/knockdown samples

    • Use gradient gels for better separation

• Inconsistent phospho-STK39 detection:

  • Problem: Rapid dephosphorylation during sample handling

  • Solution:

    • Add phosphatase inhibitors immediately to samples

    • Keep samples ice-cold throughout preparation

    • Process samples quickly without delays

    • Use phospho-blocking peptides as controls

    • Consider using protein crosslinking before lysis

• Species cross-reactivity issues:

  • Problem: Antibody doesn't detect STK39 in your species of interest

  • Solution:

    • Verify sequence homology in the epitope region

    • Choose antibodies raised against conserved regions

    • Select antibodies validated for your species

    • Consider using recombinant monoclonal antibodies for consistent results

For optimal results with STK39 phospho-specific antibodies, always maintain cold temperatures during sample preparation and include phosphatase inhibitors in all buffers to preserve phosphorylation status .

How can I develop and validate a quantitative assay for measuring STK39 expression or activation in research samples?

Developing a robust quantitative assay for STK39 requires careful validation:

• ELISA development and optimization:

  • Sandwich ELISA approach:

    • Coat plates with capture antibody (1:5000 dilution)

    • Incubate with samples and standards

    • Detect with detection antibody (suggested pair: catalog #83081-2-PBS (capture) and #83081-4-PBS (detection))

  • Key validation parameters:

    • Generate standard curve using recombinant STK39 protein

    • Determine limit of detection and quantification

    • Assess intra- and inter-assay variability (CV <15%)

    • Confirm linearity in various sample dilutions

    • Test recovery of spiked standards

• Western blot quantification:

  • Establish loading controls:

    • Use housekeeping proteins (β-actin, GAPDH) for normalization

    • Include recombinant STK39 protein standards on each gel

  • Image acquisition:

    • Use digital imaging systems with wide dynamic range

    • Avoid saturated signals

    • Perform multiple exposures if necessary

  • Densitometric analysis:

    • Use software that corrects for background

    • Generate standard curves from recombinant protein

    • Normalize target bands to loading controls

• Flow cytometry quantification:

  • Single-cell quantification workflow:

    • Fix and permeabilize cells appropriately (methanol for phospho-epitopes)

    • Stain with directly-conjugated STK39 antibodies or primary/secondary combinations

    • Include isotype controls and unstained samples

  • Calibration approaches:

    • Use quantitative fluorescent beads

    • Perform parallel analyses of standards with known STK39 levels

    • Express results as molecules of equivalent soluble fluorochrome (MESF)

• Cytometric bead array (CBA):

  • Multiplex quantification protocol:

    • Use validated antibody pairs (e.g., #83081-2-PBS capture and #83081-4-PBS detection)

    • Create standard curves with purified protein

    • Run samples alongside standards

    • Analyze with flow cytometer or specialized plate readers

• qPCR for mRNA quantification:

  • Design primers spanning exon junctions

  • Validate primer efficiency using standard curves

  • Use reference genes appropriate for your tissue/cell type

  • Calculate relative expression using 2^(-ΔΔCt) method

  • Correlate mRNA with protein levels to establish relationship

In validation experiments, samples from STK39 knockout models or cells treated with STK39-specific siRNAs should be included as negative controls to establish assay specificity . For phospho-specific assays, treatment with lambda phosphatase serves as an effective negative control.

How can I successfully implement STK39 knockdown or knockout strategies in experimental models?

Implementing effective STK39 knockdown or knockout requires strategic approaches:

• siRNA-mediated knockdown:

  • Design considerations:

    • Target conserved exons

    • Avoid regions with SNPs

    • Check for off-target effects using BLAST

    • Use 2-3 different siRNAs to confirm phenotypes

  • Transfection optimization:

    • Determine optimal cell density (typically 50-70% confluence)

    • Test multiple transfection reagents

    • Optimize siRNA concentration (10-50 nM range)

  • Validation:

    • Confirm knockdown by Western blot 48-72 hours post-transfection

    • Studies have shown successful STK39 knockdown in HCC cell lines (HuH7, HCCLM3, Hep3B)

• shRNA-mediated stable knockdown:

  • Vector selection:

    • Choose appropriate promoter (U6, H1 for RNA polymerase III)

    • Include selection marker (puromycin, G418)

  • Cloning strategy:

    • Design complementary oligonucleotides with appropriate overhangs

    • Ligate into digested vector

    • Verify construct by sequencing

  • Stable cell line generation:

    • Transduce cells with lentiviral particles

    • Select with appropriate antibiotic

    • Isolate and expand single clones

    • Validate knockdown efficiency by Western blot and qPCR

• CRISPR/Cas9 knockout:

  • Guide RNA design:

    • Target early exons

    • Use validated STK39 target sequence: 5'-CGGCGGCACAGGCTGTCGGC-3'

    • Check for off-target effects using prediction tools

  • Delivery method selection:

    • Plasmid-based (e.g., LentiCRISPRv2)

    • Ribonucleoprotein complex

  • Knockout validation:

    • Western blotting with anti-STK39 antibody

    • Genomic DNA sequencing of target region

    • Functional assays to confirm loss of activity

• Phenotypic analysis:

  • Cell proliferation:

    • Use trypan blue exclusion or CCK8 assay

    • Monitor growth curves over 5-7 days

    • Perform colony formation assays

  • Cell cycle analysis:

    • Stain with propidium iodide

    • Analyze by flow cytometry

    • STK39 knockdown arrests cells in G2/M phase

  • Apoptosis assessment:

    • TUNEL assay

    • Annexin V/PI staining

    • STK39 knockdown increases apoptosis in HCC cells

• Rescue experiments:

  • Express siRNA/shRNA-resistant STK39 cDNA

  • Introduce into knockdown cells

  • Verify expression by Western blot

  • Assess functional rescue of phenotypes

  • Studies have shown successful rescue of growth phenotypes in STK39-knockout HuH7 cells

Research has demonstrated that knockdown of STK39 significantly attenuates growth and metastasis of HCC cells both in vitro and in vivo, validating these approaches for studying STK39 function .

What are emerging areas of STK39 research and how might antibody technologies evolve to address these needs?

Emerging areas in STK39 research and advancing antibody technologies:

• Single-cell analysis of STK39 activation:

  • Current limitations:

    • Bulk tissue analysis obscures cellular heterogeneity

    • Low sensitivity for detecting minor activated populations

  • Future antibody technologies:

    • Ultra-bright fluorophore conjugates for improved sensitivity

    • Proximity ligation assay (PLA)-compatible antibody pairs for detecting STK39 interactions

    • Mass cytometry (CyTOF) compatible metal-conjugated antibodies

    • Click chemistry-enabled antibodies for multiplexed detection

• Spatial profiling of STK39 signaling networks:

  • Research direction:

    • Understanding subcellular localization of active STK39

    • Mapping spatial relationship with interaction partners (PLK1)

  • Antibody technology needs:

    • Super-resolution microscopy compatible antibodies (smaller size)

    • Multi-epitope targeting antibodies for improved spatial resolution

    • Antibody panels for simultaneous detection of STK39 and its signaling partners

    • Spatial transcriptomics-compatible antibodies

• STK39 as a therapeutic target in cancer:

  • Emerging research:

    • STK39 overexpression in 62.5% of HCC patients

    • Role in promoting cell proliferation and metastasis

  • Antibody technology developments:

    • Activity-blocking antibodies targeting STK39 kinase domain

    • Antibody-drug conjugates for targeted therapy

    • Intrabodies for disrupting specific STK39 interactions

    • Bispecific antibodies targeting STK39 and critical partners

• STK39 in hypertension precision medicine:

  • Future research direction:

    • Genotype-specific STK39 activation patterns

    • Personalized hypertension treatment based on STK39 variants

  • Antibody technology needs:

    • Allele-specific antibodies detecting variant-specific conformations

    • Quantitative assays with increased sensitivity for minor activation differences

    • Point-of-care compatible antibody formats

• Structural dynamics of STK39 activation:

  • Research focus:

    • Understanding conformational changes during activation

    • Structure-based drug design targeting STK39

  • Antibody technology evolution:

    • Conformation-specific antibodies detecting active/inactive states

    • Single-domain antibodies (nanobodies) for crystallization support

    • Structure-guided recombinant antibody engineering

    • Antibody-based biosensors for real-time activation monitoring

These emerging research areas will drive the development of more sophisticated antibody technologies, including highly specific recombinant monoclonal antibodies with batch-to-batch consistency , enabling more precise investigation of STK39 biology in both basic research and clinical applications.

How might STK39 antibodies contribute to translational research connecting basic science findings to clinical applications?

STK39 antibodies can bridge basic science and clinical applications through these translational approaches:

• Biomarker development for disease stratification:

  • Clinical need: Identifying patients likely to benefit from targeted therapies

  • Antibody-based approaches:

    • Immunohistochemistry scoring systems for STK39 expression in tumors

    • Phospho-STK39 detection in tissue microarrays for activation status

    • Multiplex IHC panels combining STK39 with other pathway markers

  • Translational potential:

    • Prognostic value (high STK39 expression correlates with poor survival in HCC)

    • Patient stratification for clinical trials targeting STK39 or downstream pathways

• Companion diagnostics for precision medicine:

  • Hypertension management:

    • Antibody-based assays to measure STK39 activation in blood cells

    • Correlation with SNP genotypes (rs6749447, rs3754777)

    • Prediction of response to specific antihypertensive medications

  • Cancer therapeutics:

    • Measuring ERK pathway activation downstream of STK39

    • Monitoring PLK1-STK39 interaction as predictive biomarker

    • Validating response to targeted therapies in real-time

• Liquid biopsy development:

  • Technical approach:

    • Ultra-sensitive ELISA/chemiluminescent immunoassays for STK39/phospho-STK39

    • Detection in circulating tumor cells using antibody-based capture

    • Exosomal STK39 quantification as surrogate for tumor status

  • Clinical applications:

    • Minimally invasive monitoring of treatment response

    • Early detection of recurrence

    • Longitudinal tracking of disease progression

• Therapeutic antibody development:

  • Target validation:

    • Using current research antibodies to validate functional domains

    • Identifying critical epitopes for therapeutic targeting

  • Therapeutic strategies:

    • Function-blocking antibodies preventing STK39-PLK1 interaction

    • Antibody-drug conjugates for targeted delivery to STK39-overexpressing cells

    • Intracellular antibody delivery systems targeting activated STK39

• Drug development support:

  • High-throughput screening:

    • Phospho-specific antibodies for measuring STK39 inhibition

    • Cell-based assays with antibody readouts

  • Pharmacodynamic biomarkers:

    • Monitoring STK39 pathway inhibition in clinical samples

    • Correlating with clinical response

    • Establishing optimal biological dose

By developing standardized, validated antibody-based assays for STK39 detection, researchers can accelerate the translation of basic findings on STK39's role in cancer progression and hypertension into clinically meaningful applications.